



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/725</b>	<b>A3</b>	(11) International Publication Number: <b>WO 96/05845</b> (43) International Publication Date: 29 February 1996 (29.02.96)
<p>(21) International Application Number: PCT/CA95/00467</p> <p>(22) International Filing Date: 2 August 1995 (02.08.95)</p> <p>(30) Priority Data: 2,130,762 24 August 1994 (24.08.94) CA</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/200,309 (CIP) Filed on 23 February 1994 (23.02.94)</p> <p>(71) Applicant (for all designated States except US): HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): TURLEY, Eva, Anne [CA/CA]; Apartment #217, 167 Bannatyne Avenue, Winnipeg, Manitoba R3B 0R4 (CA). ASCULAI, Samuel, Simon [US/CA]; Apartment #TH13, 53 McCaul Street, Toronto, Ontario M6M 2B6 (CA).</p> <p>(74) Agents: HUGHES, Ivor, M. et al.; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).</p>	<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 11 April 1996 (11.04.1996)</p>	
<p>(54) Title: TREATMENT OF DISEASE AND CONDITIONS ASSOCIATED WITH MACROPHAGE INFILTRATION IN PARTICULAR STROKE AND MYOCARDIAL INFARCTION</p> <p>(57) Abstract</p> <p>Use of hyaluronic acid and/or salts thereof for the treatment of a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into an area damaged by the disease or condition, wherein said use comprises the use of an effective amount of hyaluronic acid and/or salts thereof for a period of time until such use is no longer required.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 95/00467

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/725

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 04058 (NORPHARMCO INC) 4 April 1991	11-14
Y	see page 61, paragraph 1; claims 1-6,46-80,82,139; examples XX,XL see page 59, paragraph 4-6 see page 34, line 5 - page 35, line 30 ---	1-10,13, 15-33
X	EP,A,0 557 118 (NORPHARMCO INC) 25 August 1993  see page 2-3; claims 1-18 ---	1,2,11, 12,15, 16,25,26
Y	US,A,4 725 585 (WENGE PER S W ET AL) 16 February 1988 see the whole document ---	1-10, 15-33
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

31 January 1996

Date of mailing of the international search report

20.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Foerster, W

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 95/00467

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. CLIN. INVEST., vol. 88, November 1991 pages 1622-1628, A. WALDENSTRÖM ET AL. 'Accumulation of hyaluronan and tissue edema in experimental myocardial infarction' see page 1622 see page 1627-8 ---	1-10, 15-33
Y	TEX. REP. BIOL. MED., vol. 39, 1979 pages 339-355, M.R. SHETLAR ET AL. 'Healing of myocardial infarction in animal models' see page 344-345 see page 348 see page 352 ---	1-10, 15-33
X,Y	EP,A,0 197 718 (FIDIA SPA) 15 October 1986 see page 6-16 ---	13
X	WO,A,93 16732 (NORPHARMCO INC) 2 September 1993 see page 75; example 1C -----	11,12

## INTERNATIONAL SEARCH REPORT

...information on patent family members

International Application No

PCT/CA 95/00467

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9104058	04-04-91	AP-A- 175	03-04-92
		AT-T- 131068	15-12-95
		AU-B- 5227493	03-03-94
		AU-B- 6433090	18-04-91
		CN-A- 1051503	22-05-91
		DE-D- 69024039	18-01-96
		EP-A- 0445255	11-09-91
		EP-A- 0656213	07-06-95
		HU-A- 64699	28-02-94
		JP-T- 4504579	13-08-92
		LT-A, B 1582	26-06-95
EP-A-0557118	25-08-93	CA-A- 2061567	21-08-93
US-A-4725585	16-02-88	NONE	
EP-A-0197718	15-10-86	AU-B- 592077	04-01-90
		BE-A- 904547	03-10-86
		CH-A- 672886	15-01-90
		DE-D- 3689384	27-01-94
		DE-T- 3689384	07-07-94
		EP-A- 0555898	18-08-93
		FR-A- 2579895	10-10-86
		JP-A- 61236732	22-10-86
		LU-A- 86386	02-09-86
		NO-B- 174277	03-01-94
		US-A- 5166331	24-11-92
		US-A- 4736024	05-04-88
		US-A- 5442053	15-08-95
		HU-B- 208833	28-01-94
WO-A-9316732	02-09-93	CA-A- 2061703	21-08-93
		AU-B- 3488893	13-09-93
		CN-A- 1084064	23-03-94
		EP-A- 0626863	07-12-94
		FI-A- 943789	03-10-94
		JP-T- 7506812	27-07-95
		NO-A- 943044	19-10-94
		SK-A- 11193	09-09-93

**THIS PAGE BLANK (USPTO)**

**PCT**WORLD INTELLECTUAL PROPRIETY  
International B

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9605845A2

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/725</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 96/05845</b>
			<b>(43) International Publication Date:</b> 29 February 1996 (29.02.96)
<b>(21) International Application Number:</b> PCT/CA95/00467 <b>(22) International Filing Date:</b> 2 August 1995 (02.08.95) <b>(30) Priority Data:</b> 2,130,762 24 August 1994 (24.08.94) CA <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/200,309 (CIP) Filed on 23 February 1994 (23.02.94) <b>(71) Applicant (for all designated States except US):</b> HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TURLEY, Eva, Anne [CA/CA]; Apartment #217, 167 Bannatyne Avenue, Winnipeg, Manitoba R3B 0R4 (CA). ASCULAI, Samuel, Simon [US/CA]; Apartment #TH13, 53 McCaul Street, Toronto, Ontario M6M 2B6 (CA). <b>(74) Agents:</b> HUGHES, Ivor, M. et al.; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> TREATMENT OF DISEASE AND CONDITIONS ASSOCIATED WITH MACROPHAGE INFILTRATION IN PARTICULAR STROKE AND MYOCARDIAL INFARCTION			
<b>(57) Abstract</b>  Use of hyaluronic acid and/or salts thereof for the treatment of a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into an area damaged by the disease or condition, wherein said use comprises the use of an effective amount of hyaluronic acid and/or salts thereof for a period of time until such use is no longer required.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**TITLE OF INVENTION**

**TREATMENT OF DISEASE AND CONDITIONS ASSOCIATED WITH MACROPHAGE INFILTRATION  
IN PARTICULAR STROKE AND MYOCARDIAL INFARCTION**

**FIELD OF INVENTION**

5                   This invention relates to the treatment of diseases and  
conditions characterized by leukocyte [e.g. white blood cells]  
infiltration into the area damaged by the disease or condition for  
example in oxygen and/or glucose deprived tissue in the human  
body. This invention finds one application in the treatment of  
10 stroke. This invention finds another application in the treatment of  
infarcts (myocardial infarction). This invention also finds  
application in the treatment of any disease or condition  
characterized by leukocyte [e.g. white blood cells] infiltration to the  
area of damaged tissue of the body.

15 **BACKGROUND OF THE INVENTION**

When tissue (and the individual cells) are deprived of  
oxygen and/or glucose, the cells and consequently the tissue made up  
by the cells are damaged. As a result, among other responses, an  
inflammatory response (reaction) is set up in the area (site) of the  
20 damage. This inflammatory response includes, among other  
responses, the migration of inflammatory cells (for example  
macrophages, neutrophils, and other white blood cells) to the site of  
the damage.

For example, during a stroke or infarct (e.g. myocardial  
25 infarction, heart attack), whatever the cause, the blood supply in the  
blood vessels is impaired and diminished. The consequences include  
deprivation of oxygen and glucose resulting in, at the very least,  
damage to the deprived areas.

This damage sets, among other responses, an  
30 inflammatory response in the area damaged with the consequent  
migration of inflammatory cells (macrophages, neutrophils and other  
white blood cells). Because of the damage (trauma) to the site,  
prostaglandin synthesis also increases.

Cerebral deprivation of oxygen and glucose in premature  
35 birth follows the same scenario - a deprivation of oxygen to the brain  
of the infant which sets up an inflammatory response (migration of  
inflammatory cells (for example macrophages, neutrophils and other

white blood cells).

It is therefore an object of this invention to provide pharmaceutical compositions (for example, injectibles (sterile)), methods of treatment, and new uses for known chemicals which  
5 reduce the damage caused to the tissue and cells (when the compositions are employed), for example, resulting from a stroke, infarct (myocardial infarction) and/or any disease or condition characterized by an inflammatory response for example by macrophage, neutrophil or other white blood cell infiltration or  
10 migration into the area of the damage.

It is a further object of this invention to provide pharmaceutical compositions, methods of treatment and new uses of known chemicals which downregulate the cells' activity (macrophages, neutrophils and other white cells) and thus modify  
15 (alter) the body's anti-inflammatory response.

Further and other objects of the invention will be realized by those skilled in the art from the following summary of invention and detailed description of embodiments thereof.

#### SUMMARY OF THE INVENTION

20 According to one aspect of the invention, when tissue and thus cells are damaged for example by being deprived of glucose and/or oxygen, the activity of inflammatory cells (for example macrophages, neutrophils and other white blood cells) will be modulated (for example their migration into the area (to the site) of  
25 damage will be diminished), by the administration of an effective amount of hyaluronic acid and/or salts thereof (for example sodium hyaluronate) at the time the area is being damaged (as for example at the time of a stroke or infarct or other disease or condition which is characterized by macrophage, neutrophile or other white blood cell  
30 infiltration into the area of the tissue damaged by the condition and/or disease or a short time thereafter. While Applicant should not be limited to the following mechanism of action of the invention, Applicant believes that the administration of the hyaluronic acid and/or salts thereof (e.g. sodium salt) blocks, for example by binding  
35 with, the hyaluronic acid (HA) receptors of the inflammatory cells (for example macrophages, neutrophils and other white blood cells), thus blocking their migration into the area of the damaged tissue.

- 3 -

The preferred form of hyaluronic acid is sodium hyaluronate having a molecular weight less than 750,000 daltons for example 10,000 - 300,000 daltons.

To supplement this inhibition (blockage) of the inflammatory response, (which inflammatory response causes the migration or infiltration of the macrophages, neutrophils or other white blood cells into the damaged area), NSAIDS may also be given with the form of hyaluronic acid which blocks (for example binds with) the HA receptors. Thus inhibition of prostaglandin synthesis can be achieved.

The hyaluronic acid and/or salts (preferably sodium hyaluronate having a molecular weight less than 750,000 daltons) may be utilized at varying doses (depending upon the method of administration) from 1-10 mg/kg body weight to 15 - 20 mg/kg of body weight or more, for example a dose in excess of 25 mg/kg and more to over 3000 mg/70 kg person. In adult human (and adult rats) excess amounts of the form of hyaluronic acid are tolerated, however in rat neonates, excess can and does cause damage.

Thus and according to another aspect of the invention when an NSAID for example indomethacin (dissolved in n-methyl glucamine (nmg)) or other NSAID is administered with greater than 200 mg hyaluronic acid per 70 kg person with 1 - 2 mg/kg body weight of the NSAID (in one instance indomethacin and NMG), no major toxic side effects occur such as gastro-intestinal distress, neurological abnormalities, depression, etc., even at elevated amounts of indomethacin (if necessary). If the amount of hyaluronic acid is decreased below that amount, the usual side effects of using an NSAID may begin to reoccur. The same can be said with other therapeutic agents, no major toxic side effects occur with the administration of greater than 200 mg hyaluronic acid (e.g., sodium hyaluronate per 70 kg-person.

Preferably (and on the basis of tests performed) each preferred dosage amount of the preferred form of hyaluronic acid, sodium hyaluronate, should be in the order of about 10-25 mg/kg body weight, for example in the order of about 1800 mg/70 kg person if administered subcutaneously for example in the back. Intravenous dosing could employ smaller (lesser) dose amounts of the form of

hyaluronic acid. Preferred amounts are 10-20 mg./kg of body weight of a human.

Presently testing in neonate rats reveals that suitable dosage amounts will establish a concentration volume of the chosen form of hyaluronic acid (for example sodium hyaluronate) of about 3 mg/ml of blood in an adult human. When administered, an amount of between about 10mg of, for example, sodium hyaluronate/kg and about 25mg of, for example, sodium hyaluronate/kg of body weight of an adult human. More recent tests with rats neonates, achieved levels of hyaluronic acid (12 hours after administration subcutaneously in the neonates) at 10 mg/kg in their blood. These amounts can be adjusted up or down as would be deemed preferable in the circumstances.

The administration preferably starts at the time of the disease or condition (for example stroke or myocardial infarction) occurring or shortly thereafter (within 24 hours) and continues until such time as not required. Preferably the level achieved is maintained in the blood. For example a level of 15 mg/kg of body weight is established in the blood, by initial intravenous administration. Then that level is maintained by for example subcutaneous administration (for example, by subcutaneous injection).

NSAIDS may be given at the same time in effective amounts (e.g. 1-2 mg/kg of body weight in the case of indomethacin.

Drugs for the treating of a myocardial infarction or stroke may also be administered such as a clot dissolving drug. Clot dissolving drugs comprise TPA, Streptokinase (proteolytic product), Urokinase and the like. Other available drugs are the NSAID acetylsalicylic acid (aspirin), beta blockers, heparin, a plasminogen activator, and other suitable drugs.

In addition to the NSAIDS, other drugs (where a stroke is or has occurred) may be administered with the form of hyaluronic acid (for example sodium hyaluronate having a molecular weight less than 750,000 daltons for example 300,000 daltons) with or without the NSAIDS. These drugs would be in their expected amounts. These drugs may be for example the same as above and may also comprise anti-platelet drugs for example those which alter the platelet function

(prevent aggrregation) and prevent thrombis formation (clots).

One form of hyaluronic acid and/or salts thereof (for example sodium salt) and homologues, analogues, derivatives, complexes, esters, fragments, and sub units of hyaluronic acid, preferably hyaluronic acid and salts and thereof suitable for use with Applicant's invention is a fraction supplied by Sterivet Laboratories Limited. One such fraction is a 15 ml vial of Sodium hyaluronate 20 mg/ml (300 mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The fraction also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of hyaluronic acid and/or salts thereof may be carried in a Type I borosilicate glass vial closed by a butyl stopper which does not react with the contents of the vial.

The fraction of hyaluronic acid and/or salts thereof (for example sodium salt) may comprise the following characteristics:

a purified, substantially pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of the following:

(i) a molecular weight within the range of 150,000-225,000;

(ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;

(iii) less than about 0.6% protein on a total weight basis;

(iv) less than about 150 ppm iron on a total weight basis;

(v) less than about 15 ppm lead on a total weight basis;

(vi) less than 0.0025% glucosamine;

(vii) less than 0.025% glucuronic acid;

(viii) less than 0.025% N-acetylglucosamine;

(ix) less than 0.0025% amino acids;

(x) a UV extinction coefficient at 257 nm of less than about 0.275;

(xi) a UV extinction coefficient at 280 nm of less than about 0.275;

(xii) a pH within the range of 7.3-7.9.

Preferably the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000-225,000. More preferably the fraction of hyaluronic acid comprises at least one characteristic selected from the group consisting of the following characteristics:

- (i) less than about 1% sulphated mucopolysaccharides on a total weight basis;
- (ii) less than about 0.4% protein on a total weight basis;
- (iii) less than about 100 ppm iron on a total weight basis;
- (iv) less than about 10 ppm lead on a total weight basis;
- (v) less than 0.00166% glucosamine;
- (vi) less than 0.0166% glucuronic acid;
- (vii) less than 0.0166% N-acetylglucosamine;
- (viii) less than 0.00166% amino acids;
- (ix) a UV extinction coefficient at 257 nm of less than about 0.23;
- (x) a UV extinction coefficient at 280 nm of less than 0.19; and
- (xi) a pH within the range of 7.5-7.7.

Other forms of hyaluronic acid and/or its salts, and homologues, derivatives, complexes, esters, fragments and sub units of hyaluronic acid may be chosen from other suppliers, for example those described in the prior art documents previously referred to. In addition Applicants have proposed sodium hyaluronate produced and supplied by LifeCore™ Biomedical, Inc. having the following specifications

Characteristics

Appearance

Odor

Specification

White to cream  
coloured particles

No perceptible odor

- 7 -

	Viscosity Average Molecular Weight	< 750,000 Daltons
5	UV/Vis Scan, 190-820 nm	Matches reference scan
	OD, 260 nm	< 0.25 OD units
	Hyaluronidase Sensitivity	Positive response
10	IR Scan	Matches reference
	pH, 10mg/g solution	6.2 - 7.8
15	Water	8% maximum
	Protein	< 0.3 mcg/mg NaHy
	Acetate	< 10.0 mcg/mg NaHy
20	Heavy Metals, maximum ppm	
	As   Cd   Cr   Co   Cu   Fe   Pb   Hg   Ni	
	2.0   5.0   5.0   10.0   10.0   25.0   10.0   10.0   5.0	
25	Microbial Bioburden	Non observed
	Endotoxin	< 0.07EU/mg NaHy
30	Biological Safety Testing	Passes Rabbit Ocular Toxicity Test
	The administration may take place subcutaneously, intravenously or by injection.	
	<u>DETAILED DESCRIPTION OF EMBODIMENTS</u>	
35	The invention will now be illustrated with respect to the following example.	
	<u>Experiment 1</u>	
	Seven day old Fischer rat neonates were injected	

subcutaneously with sodium hyaluronate (MW 300,000 daltons) in the back 1/2 hour before the operation with 0.6 mg of sodium hyaluronate /60ul/animal. Animals were then injected once a day for seven days after the operation and euthenized 14 days after the operation. The right carotid artery was ligated for 1 hour (induced stroke). The animals were then placed in incubators containing 8% oxygen. (The left side was not tied off and provided a suitable control.) Brain damage was readily produced in control animals by day 4 and 7 as determined by nissl staining (for nerves) and for gliosis including increased staining for GFAP, connexin 43, and macrophages (ED-1 epitope). As well increased staining for hyaluronan receptors was observed with CD44 increased in macrophages and astrocytes while RHAMM was increased in neuronal cells and subsets of macrophages. As well damage was observed morphologically where neuronal loss was evident and the right half of the brain had collapsed. Animals treated with HA for 7 days were euthanized at 14 days (as were controls run with these experiments) and none of the above parameters were positive. That is there is no evidence of brain collapse, neuronal loss, macrophage influx or increase in the expression of gliotic proteins or hyaluronan receptors. The hyaluronan treated animal's brains appeared morphologically normal, although functional test for neuronal activity have not yet been done. In the absence of any obvious morphological changes, extensive functional damage would not be expected.

The dose used for each animal was 0.6mg of sodium hyaluronate (Molecular Weight 300,000 daltons) per 23g animal by subcutaneous administration so for a human of 70 kg this would mean a 1.8g subcutaneous dose/person. An intravenous dose would be smaller.

There are approximately 85 cc blood/kg in humans. Therefore an average adult would have about 6000 cc (70 kg person). Thus the concentration achieved is in the order of 0.3 mg of sodium hyaluronate/1 ml or cc of blood. Administration to achieve this concentration is in the order of 25 mg/kg of body weight for humans.

## Experiment 2

Experiment 2 repeated Experiment 1 only the right carotid artery was ligated for 3 hours (2 hours longer than the 1 hour

- 9 -

specified in Experiment 1) to accrue more brain necrosis. In Experiment 2 the same amount of sodium hyaluronate (HA) (0.6 mg of sodium hyaluronate) was administered to each neonate (regardless of the actual weight of the neonates) and each animal received an  
5 injection of sodium hyaluronate subcutaneously at the time of the operation.

Twelve hours after subcutaneous administration, blood levels of 15-20 mg/kg of HA are obtained. Continued analysis of blood levels indicates that HA levels remain at 15 mg/kg for 24 hours.

10 After the operation, we continued to inject HA in the same dosage amounts every 24 hours for 7 days. At not time during the 7 days did the HA levels drop below 15 mg/kg.

The brains of the animals (including controls) were examined at 2 weeks.

15 Of the three animals injected with HA, the brains were in the same condition as the brains of the neonates administered with HA in Experiment 1. The one control suffered excessive brain damage. As a result of these tests, we have concluded that dose amounts of as low as 1 mg/kg of body weight of the animal will be therapeutic (e.g.  
20 for blocking the infiltration of macrophages, neutrophils and other white blood cells into the area (to the site) of the stroke. Dose amounts of 10 mg or more of HA/kg of the animal (human) are preferred for example 10-20 mg/kg of body weight.

### Experiment 3

25 While humans and adult rats are able to tolerate excesses of sodium hyaluronate (HA), rat neonates are not as tolerant. Thus, in Experiment 3, where the rate neonates were smaller, dosage amounts of 25 mg/kg of HA, administered in Experiment 3, resulted in damage to the brains of the neonates.

### 30 Experiment 4

Four rats were each exposed to isoproteranol to induce myocardial infarction (heart attack) in each. The administration of isoproteranol for inducing an infarct is a commonly known technique as would be understood by persons  
35 skilled in the act and is not elaborated herein. Each of two of the rats was immediately after the infarct injected with sodium hyaluronate (Molecular Weight 300,000 daltons) (HA) in the amount of 15 mg/kg.

The subcutaneous injections continued for seven days (one subcutaneous injection each day). Twelve hours after the initial injection, the blood levels of HA were 10 mg/kgm body weight in the blood system of each rat.

5                   The other two rats were immediately after the induction of the infarct each injected subcutaneously with saline (as a control). The subcutaneous injections continued for seven days, one injection per day. The rats were then sacrificed. In the saline-treated animals, heart tissue was necrotic with massive amounts of  
10 accumulated white cells. In the HA-treated rats, no damage was observed in the heart tissue and no white cells were apparent (as determined by EO-1 staining of frozen sections).

As a result, we have concluded that dosage amounts of 10 - 25 mg/kg of body weight administered to humans is appropriate.  
15 While lesser amounts can still be therapeutic, they will not give optimal results. Optimal results are the goal in the treatment of each of a stroke and myocardial infarction.

Preferably the chosen dosage amount of the HA is initially given intravenously to establish the desired levels of HA in the blood.  
20 Thereafter, these levels are maintained for example by administration subcutaneously (subcutaneous injection). Preferred blood levels appear to be starting in the order of 10 mg/kg.

As many changes can be made to the preferred embodiments of the invention without departing from the scope of  
25 the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.

- 11 -

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE  
PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

1.           Use of hyaluronic acid and/or pharmaceutically  
5 acceptable salts thereof for the treatment of a human having a  
disease or condition characterized by macrophage, neutrophile or  
other white blood cell infiltration into an area damaged by the  
disease or condition, wherein said use comprises the use of an  
effective amount of hyaluronic acid and/or salts thereof for a period  
10 of time until such use is no longer required.
2.           The use of claim 1 wherein the effective amount of the  
form of hyaluronic acid is in the order of about 10 mg to about 25  
mg per kilogram of body weight.  
15
3.           The use of claim 1 or 2 wherein the disease or condition  
is a stroke.
4.           The use of claim 1 or 2 wherein the disease or condition  
20 is a myocardial infarction.
5.           The use of claim 1 or 2 wherein the use starts within  
about 24 hours of the detection of the disease or condition.
- 25 6.           The use of claim 1, 2, 3 or 4 wherein the hyaluronic acid  
or pharmaceutically acceptable salts thereof is sodium hyaluronate  
having a molecular weight less than 750,000 daltons.
7.           The use of claim 1, 2, 3 or 4 wherein the hyaluronic acid  
30 and/or pharmaceutically acceptable salts thereof is sodium  
hyaluronate having a molecular weight of about 300,000 daltons.
8.           The use of claim 1 wherein the concentration of the form  
of hyaluronic acid in a human after administration is at least of 3  
35 mg/ml of blood.
9.           The use of claim 1, 2, 3, 4, 5 or 6 further comprising

- 12 -

administration of an effective amount of a medicine selected from an NSAID, an anti-stroke drug, clot dissolving drug, Beta Blocker, acetylsalicylic acid, streptokinase, anti-platelet drugs, heparin or a plasminogen activator or combinations thereof.

5

10. The use of claim 1, 2, 3 or 4 wherein the blood levels of the form of hyaluronic acid is greater than 10 mg/kg of body weight.

10

11. An injectable sterile pharmaceutical formulation comprising in injectable dosage form at least 10 mg/kg of the human to whom the injectable is to be administered of hyaluronic acid and/or a pharmaceutically acceptable salt thereof such as sodium hyaluronate, having a molecular weight less than 750,000 daltons in a suitable vehicle.

15

12. The injectable formulation of claim 11 wherein the Molecular Weight of the form of hyaluronic acid is in the order of 300,000 daltons.

20

13. The injectable of claim 11 or 12 further comprising an anti-stroke drug, a clot dissolving drug, an NSAID, a Beta Blocker, acetylsalicylic acid, streptokinase, anti-platelet drugs, heparin, or a plasminogen activator or combinations thereof.

25

14. The injectable of claim 11 or 12 wherein the amount of the form of hyaluronic acid is about 25 mg/kg of the human for whom the injectable is to be administered.

30

15. A method of treating a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into the area damaged by the disease or condition, the method comprising administering to the human an effective amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof for a period of time until the administration is no longer required.

35

16. The method of claim 15 wherein the effective amount of

- 13 -

the form of hyaluronic acid is in the order of about 10 mg to about 25 mg per kilogram of body weight.

17. The method of claim 16 wherein the disease or condition  
5 is a stroke.
18. The method of claim 16 wherein the disease or condition  
is myocardial infarction.
- 10 19. The method of any of claims 15 or 16 wherein the  
treatment starts within about 24 hours of the detection of the disease  
or condition and continues until no longer required.
- 15 20. The method of any of claims 15, 16, 17 or 18 wherein the  
hyaluronic acid and/or pharmaceutically acceptable salts thereof is  
sodium hyaluronate having a molecular weight less than 750,000  
daltons.
- 20 21. The method of claim 15, 16, 17 or 18 wherein the  
hyaluronic acid and/or pharmaceutically acceptable salts thereof is  
sodium hyaluronate having a molecular weight in the order of  
300,000 daltons.
- 25 22. The method of claim 15 wherein the concentration of the  
form of hyaluronic acid in a human after administration is at least 3  
mg/ml of blood.
- 30 23. The method of claim 15, 16, 17, 18, 19 or 20 further  
comprising administration of an effective amount of a medicine  
selected from an NSAID, an anti-stroke drug as a clot dissolving drug,  
Beta blocker acetylsalicylic acid, streptokinase anti-platelet drugs,  
heparin or a plasminagen activator or combinations thereof.
- 35 24. The method of claim 15, 16, 17 or 18 wherein the blood  
levels of the form of hyaluronic acid achieved is greater than about  
10 mg/kg of body weight of the person.

25. Use of hyaluronic acid and/or pharmaceutically acceptable salts thereof for the manufacture of a dosage amount of a pharmaceutical composition for the treatment of a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into an area damaged by the disease or condition, wherein said use comprises the use of an effective amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof.
- 10 26. The use of claim 25 wherein the effective amount of the form of hyaluronic acid is in the order of about 10 mg to about 25 mg per kilogram of body weight.
- 15 27. The use of claim 25 or 26 wherein the disease or condition is a stroke.
28. The use of claim 25 or 26 wherein the disease or condition is a myocardial infarction.
- 20 29. The use of claim 25, 26, 27 or 28 wherein the hyaluronic acid and/or pharmaceutically acceptable salts thereof is sodium hyaluronate having a molecular weight less than 750,000 daltons.
- 25 30. The use of claim 25, 26, 27 or 28 wherein the hyaluronic acid and/or pharmaceutically acceptable salts thereof is sodium hyaluronate having a molecular weight of about 300,000 daltons.
31. The use of claim 25 wherein the concentration of the form of hyaluronic acid in a 70kg human after administration will be at least 3 mg/ml of blood.
- 30 32. The use of claim 25, 26, 27, 28 or 29 further comprising administration of an effective amount of a medicine selected from an NSAID, an anti-stroke drug, clot dissolving drug, Beta Blocker, acetylsalicylic acid, streptokinase, anti-platelet drugs, heparin or a plasminogen activator or combinations thereof.
- 35

- 15 -

33. The use of claim 25, 26, 27 or 28 wherein the blood levels of the form of hyaluronic acid will be greater than 10 mg/kg of body weight after administration of the dosage amount.

**THIS PAGE BLANK (USPTO)**